Nephrodi Therapeutics Inc. has entered an agreement with The McQuade Center for Strategic Research and Development LLC (MSRD), a member of the Otsuka family of pharmaceutical companies, to collaborate on the clinical development of Nephrodi's NDI-5001 for X-linked congenital nephrogenic diabetes insipidus (NDI). NDI-5001 is a kidney-targeted small molecule AMPK activator.
At the ongoing European Association for the Study of the Liver meeting, researchers from Suzhou Ribo Life Science Co. Ltd. presented preclinical data on RBD-1016 in two models of chronic hepatitis B virus (HBV) infection.
Researchers from Inipharm Inc. presented preclinical data for INI-822, a small-molecule inhibitor of HSD17B13, being developed for the treatment of liver disease.
Over the past decade there has been much research into the use of induced pluripotent stem cells (iPSCs) as a cell therapy to regenerate tissue and treat heart disease. Now, one researcher has narrowed the focus down to treating heart disease not with whole cells, but with mitochondria derived from iPSCs. Gentaro Ikeda, a researcher at the Department of Medicine at Stanford University, has worked on generating extracellular vesicles (EVs) containing mitochondria from pluripotent stem cell-derived cardiomyocytes and administering these to restore the functionality of the myocardium in a porcine model of an infarct.
While the liver is mostly known as the core of metabolism, contributing to the storage of nutrients and excretion of toxic substances, there is an increasing interest in how it interacts with the central nervous system through the liver-brain axis. At the 2023 European Association for the Study of the Liver (EASL) meeting in Vienna, Austria, group leader Kristina Schoonjans and her colleague Hadrien Demagny from the Laboratory of Metabolic Signaling at École Polytechnique Fédérale de Lausanne, Switzerland, gave talks setting out the context of inter-organ communication in liver disease, adding new findings from their research in the liver-brain axis.
Jiangsu Simcere Pharmaceutical R&D Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) targeting moiety reported to be useful for the treatment of cancer.
RSS
